Iscom and iscom-matrix enhance by intranasal route the IgA responses to OVA and rCTB in local and remote mucosal secretions

Vaccine

Volumn 17, Issue 20-21, 1999, Pages 2690-2701

  Ekström, Jill ^a   Hu, Ke Fei ^b   Bengtsson, Karin Lövgren ^b   Morein, Bror ^b  

^a NATIONAL VETERINARY INSTITUTE   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

Iscoms; Mucosal immunity; RCTB

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G2A; ISCOM;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; INTESTINE MUCOSA; INTRANASAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; CHOLERA TOXIN; FEMALE; G(M1) GANGLIOSIDE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; ISCOMS; LUNG; MICE; OVALBUMIN; RECOMBINANT PROTEINS;

EID: 0033523030     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00052-3     Document Type: Article

References (48)

1. Lycke N., Tsuji T., Holmgren J. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol. 22:1992;2277.
2. Snider D.P. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins. Crit Rev Immunol. 15:1995;317.
3. Wennerås C., Svennerholm A.M., Åhren C., Czerkinsky C. Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine. Infect Immun. 60:1992;2650.
4. Muller C.P., Beauverger P., Schneider F., Jung G., Brons N.H.C. Cholera toxin B stimulates systemic neutralizing antibodies after intranasal co-immunization with measles virus. J Gen Virol. 76:1995;1371.
5. Wu H.-Y., Russell M.W. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit. Infect Immun. 61:1993;314.
6. Wu H.-Y., Russell M.W. Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine. 16:1998;286.
7. Tochikubo K., Isaka M., Yasuda Y., Kozuka S., Matano K., Miura Y., Taniguchi T. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine. 16:1998;150.
8. Van der Heijden P.J., Bianchi A.T., Dol M., Pals J.W., Stok W., Bokhout B.A. Manipulation of intestinal immune responses against ovalbumin by cholera toxin and its B subunit in mice. Immunology. 72:1991;89.
9. Ramon G. Procédés pour accroître la production des antitoxines. Ann Inst Pasteur. 40:(1):1926.
10. Espinet E.G. Nuevo tipo de vacuna antiaftosa a complejo glucovirioco. Gac Vet. 74:1951;1.
11. Dalsgaard K. The application of the saponin adjuvant Quil A in foot-and-mouth disease vaccines. Bull Off Int Epiz. 89:1978;963.
12. Kensil C.R., Patel C., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J Immunol. 146:1991;431.
13. Kersten G.F.A., Spiekstra A., Beuvery E.C., Crommelin D.J.A. On the structure of immune-stimulating saponin-lipid complexes (iscoms). Biochim Biophys Acta. 1062:1991;165.
14. Lucy J.A., Glauert A.M. Structure and assembly of macromolecular lipid complexes composed of globular micelles. J Mol Biol. 8:1964;727.
15. Morein B., Sundquist B., Höglund S., Dalsgaard K., Osterhaus A. Iscom, a novel structure of antigenic presentation of membrane proteins from enveloped viruses. Nature. 308:1984;457.
16. Morein B., Lövgren K., Rönnberg B., Sjölander A., Villacrés-Eriksson M. Immunostimulating complexes: clinical potential in vaccine development. Clin Immunother. 3:1995;461.
17. Morein B., Lövgren Bengtsson K., Cox J. Modern adjuvants. Functional aspects. Kaufmann S.H.E., Concepts in vaccine development. 1996;243-263 Walter de Gruyter, Berlin, New York.
18. Rönnberg B., Fekadu M., Morein B. Adjuvant activity of non-toxic Quillaja saponaria Molina components for use in iscom-matrix. Vaccine. 13:1995;1375.
19. Villacres-Eriksson M. Antigen presentation by naive macrophages, dendritic cells and B-cells to primed T-lymphocytes and their cytokine production following exposure to immunostimulating complexes. Clin Exp Immunol. 102:1995;46.
20. Behboudi S., Morein B., Villacres-Eriksson M. In vivo and in vitro induciton of IL-6 by Quillaja Saponaria Molina triterpenoid formulations. Cytokine. 9:1997;682.
21. Villacres-Eriksson M., Behboudi S., Morgan A.J., Trinchieri G., Morein B. Immunomodulation by Quillaja saponaria adjuvant formulations: in vivo stimulation of interleukin 12 and its effects on the antibody response. Cytokine. 9:1997;73.
22. Heeney J.L., van Gils M.E., van der Meide P., de Giuli Morghen C., Ghioni C., Gimelli M., Raddelli A., David D., Åkerblom L., Morein B. The role of type-1 and type-2 T-helper immune responses and HIV-1 vaccine protection. J Med Primatol. 27:1998;50-58.
23. Maloy K.J., Donachie A., Mowat A.M. Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with iscoms. Eur J Immunol. 25:1995;3835.
24. Dotsika E., Karagouni E., Sundquist B., Morein B., Morgan A., Villacrés-Eriksson M. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus (EBV) iscoms. Scand J Immunol. 45:1997;261.
25. Hansen D.S., Villacres-Eriksson M., Åkerblom L., Hellman U., Segura E., Carlomagno M., Morein B. An immunoaffinity purified Trypanosoma cruzi antigen suppresses cellular proliferation through a TGF-β mediated mechanism. Scand J Immunol. 47:1998;509.
26. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., Berzofsky J.A. Induction of CD8+ cytotoxic T-cells by immunization with purified HIV-1 envelope protein in iscoms. Nature. 344:1990;873.
27. Villacres M.C., Behboudi S., Nikkila T., Lövgren-Bengtsson K., Morein B. Internalization of iscom-borne antigens and presentation under MHC class I or class II restriction. Cell Immunol. 185:1998;30.
28. Villacres-Eriksson M. Induction of immune response by iscoms. Dissertation, Swedish University of Agricultural Sciences, 1993.
29. Lövgren K., Kåberg H., Morein B. An experimental influenza subunit vaccine (iscom): induction of protective immunity to challenge infection in mice after intranasal or subcutaneous administration. Clin Exp Immunol. 82:1990;435.
30. Jones P.D., Tha Hla R., Morein B., Lövgren K., Ada G.L. Cellular immune responses in the murine lung to local immunization with influenza A virus glycoproteins in micelles and immunostimulatory complexes (iscoms). Scand J Immunol. 27:1988;645.
31. Mowat A.M., Maloy K.J., Donachie A.M. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigen. Immunology. 80:1993;527.
32. Bradford M.M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:1976;248.
33. Bergquist C., Lagergård T., Lindblad M., Holmgren J. Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates. Infect Immun. 63:1995;2021.
34. Hu K.-F., Elvander M., Merza M., Åkerblom L., Brandenburg A., Morein B. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses. Clin Exp Immunol. 113:1998;235.
35. Sjölander A., van't Land B., Lövgren-Bengtsson K. Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol. 177:1997;69.
36. Tamura S., Yamaka A., Shimohara M., Tomita T., Komase K., Tsuda Y., Suzuki Y., Nagamine T., Kawahara K., Danbara H., Aizawa C., Oya A., Kurata T. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine. 12:1994;419.
37. Weiner H.L. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today. 18:1997;335.
38. Mowat A.M., Viney J.L. The anatomical basis of intestinal immunity. Immunol Rev. 156:1997;145.
39. Sun J.B., Holmgren J., Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA. 91:1994;10795.
40. Smith R.E., Donachie A.M., Mclaren F.H., Mowat A.M. Preservation of mucosal and systemic adjuvant properties of ISCOMs in the absence of functional interleukin-4 or interferon-γ Immunology. 93:1998;556.
41. Bright H., Turnbull T., Toms G.L., Scott R. Comparison of the T helper cell response induced by respiratory syncytial virus and its fusion protein in BALB/c mice. Vaccine. 13:1995;915.
42. Marinaro M., Staats H.F., Hirol T., Jackson R.J., Coste M., Boyaka P.N., Okahashi N., Yamamoto M., Kiyono H., Bluethmann H., et al. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J Immunol. 155:1995;4621.
43. Lövgren Bengtsson K., Sjölander A. Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant. Vaccine. 14:1996;753.
44. Johansson E.-L., Rask C., Fredriksson M., Eriksson K., Czerkinsky C., Holmgren J. Antibodies and antibody secreting cells in the female genital tract after vaginal or intranasal immunization with cholera toxin B subunit or conjugates. Infect Immun. 66:1998;514.
45. Hu K-F, Ekström J, Merza M, Lövgren Bengtsson K, Morein B. Induction of antibody responses in the common mucasal immune system by respiratory syncytial virus immunostimulating complexes. Med Microbiol Immunol 1999, in press.
46. Rosenthal K.L., Gallichan W.S. Challenges for vaccination against sexually transmitted diseases: induction and long-term maintenance of mucosal immune responses in the female genital tract. Semin Immunol. 9:1997;303.
47. Douce G., Giuliani M.M., Giannelli V., Pizza M.G., Rappouli R., Dougan G. Mucosal immunogenicity of genetically detoxified derivates of heat labile toxin from Escherichia coli. Vaccine. 16:1998;1065.
48. Yamamoto S., Takeda Y., Yamamoto M., Kurazono H., Imaoka K., Yamamoto M., Fujihashi K., Noda M., Kiyono H., McGhee J.R. Mutants in the ADP-ribosyltransferase cleft cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med. 185:1997;1203.